ORL-1 Modulator Polymorphs for Stable Sleep Disorder Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compounds with affinity for the ORL-1 receptor lack stable solid forms, affecting their solubility, stability, and efficacy, which are critical for drug development and safety.
Innovation Solution
Development of crystalline forms of substituted-quinoxaline-type bridged piperidine compounds, characterized by specific XRPD patterns, for use in pharmaceutical compositions to treat pain and sleep disorders, ensuring high crystalline purity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If substituted-quinoxaline-type bridged piperidine compounds are developed for ORL-1 receptor affinity, then therapeutic efficacy for pain and sleep disorders is improved, but stable solid forms are lacking which affects solubility, stability, and safety
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions (temperature, solvent composition, pH, addition rate) to obtain different polymorphic forms of the same compound. This allows optimization of solid form stability while maintaining therapeutic efficacy through controlled transformation of the compound's physical state.
Solution Approach 2:
The patent utilizes phase transitions by inducing crystallization from solution to solid state, and by converting between different polymorphic forms through controlled heating or solvent addition. These phase changes enable the creation of stable solid forms with improved solubility and safety profiles while preserving the compound's biological activity.
2Reliability
If crystalline forms with high purity are produced, then safety and efficacy are improved, but the complexity of characterizing and controlling multiple polymorphic forms increases
Solution Approach 1:
The patent replaces complex mechanical mixing and filtration processes with controlled crystallization methods that spontaneously produce high-purity crystalline forms. By using solvent-based crystallization and controlled cooling, the system automatically separates the compound from impurities, reducing the need for complex mechanical separation equipment and procedures.
Solution Approach 2:
The patent introduces solvent systems as intermediaries to facilitate controlled crystallization. Solvents act as mediators that allow the compound to transition from disordered solution state to ordered crystalline state, enabling high-purity solid form production while simplifying the overall process control compared to direct precipitation methods.
3Quantity of substance
If bulk amounts of crystalline compound are produced, then pharmaceutical formulation capability is improved, but the risk of polymorphic contamination increases
Solution Approach 1:
The patent applies preliminary action by pre-establishing controlled crystallization conditions before bulk production begins. By defining specific temperature ranges, solvent compositions, and addition rates in advance, the process ensures that only the desired polymorphic form crystallizes, preventing contamination while enabling large-scale production. This preliminary protocol design allows consistent quality control across batches.
Solution Approach 2:
The patent implements feedback control by continuously monitoring crystallization progress through techniques like in-situ Raman spectroscopy or HPLC analysis. This real-time feedback allows dynamic adjustment of crystallization parameters to maintain polymorphic purity even during bulk production, ensuring that the desired crystalline form is obtained consistently at scale without contamination from alternative polymorphs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms exhibit affinity for the human ORL-1 receptor, providing effective treatment and prevention of sleep disorders, including insomnia and alcohol-induced sleep disorders, with improved stability and solubility, enhancing drug efficacy and safety.
Implementation Method 1
crystalline forms of a compound of Formula (I) with a crystalline purity of a single crystalline form that is greater than about 90%, relative to the total amount of all crystalline forms of the compound of Formula (I) present... Such crystalline forms of a compound of Formula (I) exhibit affinity for the human ORL-1 receptor
Implementation Method 2
the crystalline forms of Formula (I) provided herein are characterized by powder X-ray diffraction ('PXRD' or 'XRPD') crystallography. In one aspect of the invention, a non-solvated crystalline form of a compound of Formula (I), referred to herein as Form A, has a XRPD pattern that is substantially similar
Data Source
AI summary
Provided herein are novel crystalline forms of a crystalline compound of Formula (I), which modulates the ORL-1 receptor. The crystalline compounds of Formula (1), compositions thereof, and methods of using thereof that are described herein are particularly useful for treatment, prevention, and management of several sleep disorders.